تاثیر شیمی درمانی همراه با ملاتونین بر سرطان های انسانی: مروری

عنوان انگليسی

Adjuvant chemotherapy with melatonin for targeting human cancers: A review

خلاصه انگلیسی

Melatonin is a multifunctional hormone that has long been known for its antitumoraleffects. An advantage of the application of melatonin in cancer therapy is its ability todifferentially influence tumors from normal cells. In this review, the roles ofmelatonin adjuvant therapy in human cancer are discussed. Combination of melatoninwith chemotherapy could provide synergistic antitumoral outcomes and resolve drugresistance in affected patients. This combination reduces the dosage for chemother-apeutic agents with the subsequent attenuation of side effects related to these drugson normal cells around tumor and on healthy organs. The combination therapyincreases the rate of survival and improves the quality of life in affected patients.Cancer cell viability is reduced after application of the combinational melatonintherapy. Melatonin does all these functions by adjusting the signals involved in cancerprogression, re‐establishing the dark/light circadian rhythm, and disrupting the redoxsystem for cancer cells. To achieve effective therapeutic outcomes, melatoninconcentration along with the time of incubation for this indoleamine needs to beadjusted. Importantly, a special focus is required to be made on choosing anappropriate chemotherapy agent for using in combination with melatonin. Because ofdifferent sensitivities of cancer cells for melatonin combination therapy, cancer‐specific targeted therapy is also needed to be considered. For this review, thePubMed database was searched for relevant articles based on the quality of journals,the novelty of articles published by the journals, and the number of citations per yearfocusing only on human cancers.

Document Downloads